Switzerland-based dairy ingredients and infant-formula supplier Hochdorf has once again revised its annual forecast downwards.

It is the second time Hochdorf has made such a move in the last four months.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In a statement, the company said the move is based on sales still expected this year.

Hochdorf now expects net revenues in the range of CHF540m-570m (US$546.1m-576.5m) for 2018 as well as a percentage EBIT in comparison to production revenues of 3.5-4%.

Previously, Hochdorf had assumed sales of CHF570m to 600m and had forecast its EBIT margin to be 5.8% to 6.5%.

See Also:

Hochdorf said the outlook adjustment is based, among other things, on “year-end business” for Pharmalys Laboratories that is unexpectedly weaker than planned.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Furthermore, milk fat/butter prices in the European region have fallen, contrary to expectations. The price decline has a negative impact on the warehouse valuation and also on butter selling prices, especially at Uckermärker Milch,” it said.

“These two factors will influence both sales and the Hochdorf Group result.”

In its last downgrade in August, Hochdorf blamed the cost and delays linked to a new production line in Sulgen, Switzerland, a lack of turnover in China and the sale of the Hochdorf Baltic Milk business.

Alain Oberhuber, a Switzerland-based analyst covering Hochdorf at German bank MainFirst, said today (10 December): “We are surprised about the high earnings volatility of Pharmalys. At the first-half interim results Hochdorf was still guiding for EBIT at Pharmalys for financial year 2018 of CHF28-30m. The current guidance now stands at CHF20m. The Swiss baby care business’ EBIT guidance remains at CHF10m for financial year 2018. So, total baby care business is now more at CHF30m versus CHF38m.”